Schedules of rituximab maintenance.
| Reference . | Patient population . | Maintenance schedule . |
|---|---|---|
| Abbreviations: SLL, small lymphocytic leukemia; EORTC, European Organization for Research on Treatment of Cancer. | ||
| Hainsworth et al7 | Untreated follicular and SLL | Induction: Rituximab monotherapy (375 mg/m2 weekly × 4 weeks) 375 mg/m2 weekly × 4 weeks every 6 months × 3 times |
| Ghielmini et al8 | Untreated and relapsed follicular lymphoma | Induction: Rituximab monotherapy (375 mg/m2 weekly × 4 weeks) 375 mg/m2 at month 2,4,6,8 after end of induction |
| Gordan et al9 | Patients with CD20+ lymphoproliferative disorders who had received at least 1 prior treatment | 375 mg/m2 every time rituximab blood levels fall under 25 mg/mL (375 mg/m2 given every 3–4 months) |
| Hagenbeek et al EORTC10 | Relapsed follicular lymphoma | 375 mg/m2 every 3 months × 2 years |
| Reference . | Patient population . | Maintenance schedule . |
|---|---|---|
| Abbreviations: SLL, small lymphocytic leukemia; EORTC, European Organization for Research on Treatment of Cancer. | ||
| Hainsworth et al7 | Untreated follicular and SLL | Induction: Rituximab monotherapy (375 mg/m2 weekly × 4 weeks) 375 mg/m2 weekly × 4 weeks every 6 months × 3 times |
| Ghielmini et al8 | Untreated and relapsed follicular lymphoma | Induction: Rituximab monotherapy (375 mg/m2 weekly × 4 weeks) 375 mg/m2 at month 2,4,6,8 after end of induction |
| Gordan et al9 | Patients with CD20+ lymphoproliferative disorders who had received at least 1 prior treatment | 375 mg/m2 every time rituximab blood levels fall under 25 mg/mL (375 mg/m2 given every 3–4 months) |
| Hagenbeek et al EORTC10 | Relapsed follicular lymphoma | 375 mg/m2 every 3 months × 2 years |